A global evaluation of voriconazole activity tested against recent clinical isolates of Candida spp.
Voriconazole susceptibility testing was performed on 7191 Candida spp. from 78 centers worldwide between 2004 and 2007. Voriconazole was very active in vitro (MIC(50)/MIC(90), 0.008/0.25 microg/mL; 98% susceptible). In comparison to 5866 Candida spp. isolates collected during global surveillance from 1997 to 2001, there were no changes in voriconazole mean MIC or MIC distribution.
Diekema
Daniel J
DJ
Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, IA 52242, USA. daniel-diekema@uiowa.edu
Messer
Shawn A
SA
Hollis
Richard J
RJ
Boyken
Linda
L
Tendolkar
Shailesh
S
Kroeger
Jennifer
J
Jones
Ronald N
RN
Pfaller
Michael A
MA
D000935:Antifungal Agents / Q000494:pharmacology*; D002175:Candida / Q000187:drug effects* / Q000302:isolation & purification; D002177:Candidiasis / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology*; D025141:Drug Resistance, Fungal; D014943:Global Health; D006801:Humans; D008826:Microbial Sensitivity Tests; D011159:Population Surveillance; D011743:Pyrimidines / Q000494:pharmacology*; D014230:Triazoles / Q000494:pharmacology*; D065819:Voriconazole
D000935:Antifungal Agents; D011743:Pyrimidines; D014230:Triazoles; D065819:Voriconazole